微創醫療(00853.HK)年度由盈轉虧1.91億美元
格隆匯3月30日丨微創醫療(00853.HK)公佈，截至2020年12月31日止年度，公司收入6.49億美元，同比減少18.2%；毛利4.36億美元，同比減少22.7%；公司股東應占虧損1.91億美元，上年同期溢利4628萬美元；每股虧損10.97美分。
收益下降主要受新型冠狀病毒肺炎疫情導致手術擇期等因素影響。但心臟瓣膜業務、大動脈及外周血管介入產品業務及神經介入產品業務仍然保持快速增長態勢，分別錄得剔除匯兑影響後收入增長383.4%、40.9%及17.5%。
由盈轉虧主要歸因於(i)受新型冠狀病毒肺炎疫情及中國冠脈支架集中帶量採購政策的影響，收入下降；(ii)對持續進行的研發項目及新展開的研發項目的投資增加；(iii)報吿期內根據股份獎勵計劃對若干僱員包括一名執行董事授予激勵股票；(iv)未有上年同期處置上海微創電生理醫療科技股份有限公司部分股權獲取的一次性投資收益。
研發成本由上年度的151.5百萬美元增加27.2%至該年度的192.6百萬美元。該增加主要由於對持續進行的研發項目及新展開的研發項目的投資增加。
報吿期內，基於財務報吿可呈報分部，本集團共擁有八個主要業務板塊，即心血管介入產品業務、骨科醫療器械業務、心律管理業務、大動脈及外周血管介入產品業務、神經介入產品業務、心臟瓣膜業務、手術機器人業務和外科醫療器械業務，共生產300餘個醫療器械產品，向醫生和患者提供近300項醫療解決方案，於超過80個國家或地區覆蓋10,000多家醫院。
報吿期內，集團繼續充實並穩固現有團隊，着力推進市場滲透，尤其在縣級市場加大醫院准入力度。藥物洗脱支架於報吿期內共覆蓋2,400多家醫院，其中Firehawk覆蓋醫院同比增長27%，Firebird2覆蓋醫院同比增長14%。除現有的四款藥物洗脱支架和四款球囊產品之外，集團於報吿期內亦在可吸收支架、旋磨導管、震波球囊、藥物球囊等多個產品領域取得了階段性成果。
於2020年，集團的研發項目取得豐碩成果，共有30款產品獲得國家藥品監督管理局頒發的註冊證，2款產品進入綠色通道。自綠色通道建立以來，截至2020年底，集團共有二十款產品獲批進入綠色通道，連續六年在醫療器械行業排名第一。國際市場上，集團亦有4項產品獲得FDA批准，14項產品獲得CE批准。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
